Fig. 3: MCL-1i-induced MYC downregulation and STAT1 upregulation contribute to the development of resistance to MCL-1 inhibition.
From: Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma
A Western blot analysis showing decreased MYC and increased phosphorylated STAT1 (p-STAT1) and total STAT1 levels in MYC knockdown (+) cell lines compared to parental controls (–). B Western blot showing increased p-STAT1 and total STAT1 levels in MYC-off P493-6 cells by 1 μM doxycycline treatment. C Western blot analysis of cleaved PARP (c-PARP) and MYC protein expression in parental (sgCtrl) and MYC knockdown (sgMYC) cell lines treated with the indicated concentrations of S63845 for 24 h (left). Cell viability assay demonstrating enhanced proliferation of MYC knockdown cells (Z138) following S63845 treatment compared to parental cells (right). D Western blot analysis of cleaved PARP (c-PARP) and STAT1 expression in S63845-resistant cell lines (sgCtrl) and corresponding STAT1 knockdown cell lines (sgSTAT1) treated with the indicated doses of S63845 for 24 h (left). Cell viability assay showing reduced proliferation in STAT1 knockdown S63845-resistant cell lines (HBL-2, right). Data shown in (C, D) are representative of at least three independent experiments.
